In addition, SIRT1 overexpression significantly enhanced the resistance to cisplatin and paclitaxel in endometrial carcinoma cell lines, thus using the SIRT1 inhibitor (EX527) to suppress the proliferation of these cells [122]. This evidence concerns the gene SIRT1 and endometrial carcinoma.